132 related articles for article (PubMed ID: 37130758)
1. The Prevalence of Prostate Cancer Among Young Men Below 55 Years of Age in Nigeria.
Ntekim A; Folasire A; Odukoya OA
Cancer Control; 2023; 30():10732748231175255. PubMed ID: 37130758
[TBL] [Abstract][Full Text] [Related]
2. Awareness and Attitudes of Nigerian Men Living in Abuja on Prostate Cancer and Screening.
Farazi PA; Siahpush M; Maloney S; Dinkel D; Michalek A; John R; Oluwole O
J Cancer Educ; 2019 Dec; 34(6):1107-1111. PubMed ID: 30116988
[TBL] [Abstract][Full Text] [Related]
3. The Prevalence of Zinc Deficiency among Men with and without Prostate Cancer in Port Harcourt, Nigeria.
Amadi C; Aleme BM
Nutr Cancer; 2020; 72(6):1018-1025. PubMed ID: 31522560
[No Abstract] [Full Text] [Related]
4. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination.
Ikuerowo SO; Omisanjo OA; Bioku MJ; Ajala MO; Mordi VP; Esho JO
Pan Afr Med J; 2013; 15():129. PubMed ID: 24255735
[TBL] [Abstract][Full Text] [Related]
5. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
6. A comparison of clinicopathologic features of prostate cancer between Nigerian and South African black men.
Ahmed RO; Sewram V; Oyesegun AR; Ayele B; van Wyk A; Fernandez P
Afr J Urol; 2022; 28(1):6. PubMed ID: 35280496
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Cadmium exposure and the risk of prostate cancer among Nigerian men: Effect modification by zinc status.
Bede-Ojimadu O; Nnamah N; Onuegbu J; Grant-Weaver I; Barraza F; Orakwe J; Abiahu J; Orisakwe OE; Nriagu J
J Trace Elem Med Biol; 2023 Jul; 78():127168. PubMed ID: 37043921
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years.
Baniak N; Sholl LM; Mata DA; D'Amico AV; Hirsch MS; Acosta AM
Histopathology; 2021 May; 78(6):857-870. PubMed ID: 33306242
[TBL] [Abstract][Full Text] [Related]
10. Primary cancers before and after prostate cancer diagnosis.
Van Hemelrijck M; Drevin L; Holmberg L; Garmo H; Adolfsson J; Stattin P
Cancer; 2012 Dec; 118(24):6207-16. PubMed ID: 22674346
[TBL] [Abstract][Full Text] [Related]
11. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
12. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
13. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
14. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
[TBL] [Abstract][Full Text] [Related]
15. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study.
Xu X; Kharazmi E; Tian Y; Mukama T; Sundquist K; Sundquist J; Brenner H; Fallah M
PLoS Med; 2021 Jun; 18(6):e1003616. PubMed ID: 34061847
[TBL] [Abstract][Full Text] [Related]
16. Unusual presentation of advanced prostate cancer in a black population of South-Western Nigeria.
Salako A; Badmus T; Komolafe A; David R; Igbokwe M; Laoye A; Akinbola I; Babalola R; Onyeze C
Pan Afr Med J; 2019; 32():15. PubMed ID: 31143320
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer knowledge gaps among community stakeholders in rural Nigeria: implications for seeking screening.
Adedeji IA; Lawal SA; Aluko-Arowolo S
Cancer Causes Control; 2021 Aug; 32(8):895-901. PubMed ID: 33991283
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening: what do men know, think and do about their risk? exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey.
Ugochukwu UV; Odukoya OO; Ajogwu A; Ojewola RW
Pan Afr Med J; 2019; 34():168. PubMed ID: 32153708
[TBL] [Abstract][Full Text] [Related]
19. Incidence of second malignancies for prostate cancer.
Van Hemelrijck M; Feller A; Garmo H; Valeri F; Korol D; Dehler S; Rohrmann S
PLoS One; 2014; 9(7):e102596. PubMed ID: 25047238
[TBL] [Abstract][Full Text] [Related]
20. Increased incidence of prostate cancer in Nigerians.
Ogunbiyi JO; Shittu OB
J Natl Med Assoc; 1999 Mar; 91(3):159-64. PubMed ID: 10203918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
